Posts Tagged ‘senator grassley’

Doctor Who Criticizes Senators For “Attacking” Pharma in Washington Times Article Failed to Mention He’s Served Prison Time for Fraud

Thursday, March 4th, 2010

By Allen Jones
Former Investigator,
Pennsylvania Office of the Inspector General

On March 4, 2010, The Washington Times posted a scathing op-ed by Dr. Gilbert Ross in which Ross slammed Senator Grassley, Senator Baucus and FDA Whistleblower David Graham.   In a rambling tirade Ross accuses the trio of tinkering with the practice of medicine by unfairly criticizing pharmaceutical companies and defends GlaxoSmithKline (GSK) and their discredited drug Avandia.

Ross fails to disclose that he has a personal reason for being angry with the Federal Government. In June of 1993, Ross was found guilty in Federal Court of 13 counts of fraud in a scheme to operate medical clinics for the purpose of obtaining payments directly and indirectly from the Medicaid system. He served 2 years in Federal Prison. http://w3.health.state.ny.us/opmc/factions.nsf/0522fed2dd2160ff852568c0004e894a/85b1e5abf211b2a585256a4a0047eb10/$FILE/ATTH2LGV/lc116347.pdf

Ross is identified as “medical director of the American Council on Science and Health,” but Ross discloses no financial ties to GSK.  The ACSH website however acknowledges that 40% of ACSH’s budget comes from “corporations.”  Does this include Pharma funding? http://www.acsh.org/about/pageID.85/default.asp

It is disgraceful that The Washington Times would post Ross’ criticism of great men and their worthy cause without disclosing very relevant facts relating to Ross’ credibility.

Allen Jones worked as an investigator in the Pennsylvania Office of the Inspector General (OIG), and gained widespread national and international attention as a whistleblower after uncovering pharmaceutical industry payments to government officials for the purpose of implementing a national mental health screening/psychotropic drug treatment plan based on the controversial Texas Medication Algorithm Project (TMAP). In May 2004, the British Medical Journal reported Jones had uncovered evidence major drug companies sought to influence government officials.

« Return to news items


  • Share/Bookmark

How Vested Interests Created the Perfect Marketing/Lobbying Machine: Mental Health “Advocacy” Groups—Funded by Pharma

Thursday, December 10th, 2009

by CCHR International

An ongoing U.S. Senate investigation headed by Senator Charles Grassley has  sought disclosure of pharmaceutical funding paid to researchers, physicians,  medical schools and medical journals.  Some of the nation’s most prominent psychiatrists have now been exposed for extensive conflicts of interest amounting to millions in undisclosed pharmaceutical funding, including Dr. Charles Nemeroff, Dr. Joseph Biederman, Dr. Melissa DelBello, Dr. Timothy Wilens, Dr. Thomas Spencer, Dr. Alan Schatzberg, Dr. Martin Keller, Dr. A. John Rush, Dr. Karen Wagner, Dr. Jeffrey Bostic and Dr. Frederick Goodwin — many of which serve as advisory board members to mental illness “advocacy groups” which are now also the subject of the Senate investigation for their undisclosed pharmaceutical funding.

The majority of the public may or may not be familiar with these so-called mental health advocacy organizations, such as the National Alliance on Mental Illness (NAMI), Children and Adults with Attention Deficit Hyperactivity Disorder (CHADD) or the myriad of bipolar, depression or ADHD “support groups” that are inundating the internet.

But they need to be.

These are groups operating under the guise of advocates for the “mentally ill,” which in reality are heavily funded pharmaceutical front groups – lobbying and working on state and federal laws which effect the entire nation — from our elderly in nursing homes to our military, pregnant women, nursing mothers and school children. Presenting themselves as patient advocacy groups is highly disingenuous not only to their membership, many of which may have a sincere desire to help a loved one or a family member with mental problems, but to legislators, the press and the American public — for they have consistently lobbied for legislation that benefits the mental health and pharmaceutical industries which fund them, and not patients they claim to represent.

Certainly any organization claiming to be for the rights of patients diagnosed mentally ill would have as their primary goal, full informed consent in the field of mental health – including full and complete disclosure of all drug risks, the right to refuse treatment, the right to know that psychiatric diagnoses are not medical conditions (evident by the fact there is not one confirmatory medical/scientific test). Above all such groups would provide patients with an abundance of information on non-harmful, non- drug, medical solutions and options considering the dangerous and well documented risks of psychiatric drugs by international drug regulatory agencies.

These groups do not.

A patients rights group for the mentally ill would never endorse something as absurd and obviously dangerous as giving electroshock to pregnant women, nor condone schools being able to require children to take a psychiatric drug as a condition of attending school. Furthermore, they would never be opposed to the FDA actually doing its job and finally issuing long overdue warnings that antidepressants can cause children to commit suicide, or issue warnings that ADHD drugs have serious and even deadly side effects. Yet these are just some of the actions condoned and promoted by these so-called patients rights groups.

As another example take the federally proposed bill, The Mothers Act; a previous version of this bill called on using a method of “screening” pregnant women and new mothers called EPDS, a screening method documented to triple the number of women diagnosed with Postpartum depression, according to a study published in Obstetrics & Gynecology. The Scandinavian Journal of Public Health stated that EPDS screening was unethical and should not be used. None of the so called advocacy groups for the mentally ill had any objections to this bill whatsoever, or endorsing such an unethical screening tool. They supported it. The bill would have passed with no objections from them whatsoever, if not for the dedication of real advocacy groups with no vested interests (ties to Pharma) opposing language in this bill that would have led to women being falsely diagnosed and put on dangerous psychiatric drugs to “treat” them, unnecessarily placing new mothers and their infants at great risk.

To put it simply, these groups are not what they appear to be. Yet their influence over legislation, lobbying, drug regulation (or lack thereof), and public relations campaigns is substantial and effects the entire nation. For they claim to be the voice of the “mentally ill.” But are they? Or are they the result of a brilliant marketing/lobbying campaign designed to benefit the industry that funds them—the Psycho/Pharmaceutical industry.

To find out how it all started click here: http://www.cchrint.org/psycho-pharmaceutical-front-groups/

« Return to news items


  • Share/Bookmark

U.S. Sen Grassley-Demanding transparency for Pharma funds paid to doctors, researchers, patient ‘advocacy’ groups

Thursday, November 19th, 2009

IowaPolitics.com
November 19, 2009

WASHINGTON — Senator Chuck Grassley has asked leading medical schools to describe their policies on ghostwriting as part of his continuing effort to shed light on financial ties between the pharmaceutical industry and medical professionals.

“I’m interested in transparency, and academic institutions play an important role in establishing adequate and meaningful disclosure. Letting the sun shine in and making information public is basic to building people’s confidence in medical research and the practice of medicine,” Grassley said.

Last July, Grassley wrote to eight leading medical journals to ask the same kinds of questions he’s presented to the medical schools. Prior to that, he asked two major drug companies about allegations that they hired ghostwriters to draft articles promoting company products and seek academics to sign on as primary authors.

Grassley also has conducted oversight and sought disclosure with physicians, continuing medical education and the patient advocacy community. He has worked to expose cases where there was vast disparity between drug-company payments received and reported by leading medical researchers. The National Institutes of Health is working on new disclosure guidelines for federal grant recipients in response to Grassley’s work.

In January, Grassley and Senator Herb Kohl introduced, for the second time, the Physician Payments Sunshine Act. The legislation would require annual public reporting by drug, device and biologic manufacturers of payments made to physicians nationwide. It was included in the health care reform bill passed in October by the Senate Committee on Finance.

Read entire article: http://www.iowapolitics.com/index.iml?Article=177376

« Return to news items


  • Share/Bookmark

Sen. Grassley’s bill requires disclosure of Pharma $ to doctors, ghost writers & “patient advocacy” groups like NAMI

Friday, October 23rd, 2009

IowaPolitics.com
October 23, 2009

WASHINGTON — Senator Chuck Grassley is continuing his campaign to establish transparency with the financial relationships between drug companies and medical professionals.

Grassley has conducted oversight and sought disclosure with physicians, especially those involved in influential taxpayer-sponsored medical research; medical journals containing ghostwritten articles; medical colleges; continuing medical education; and the patient advocacy community.

This week, the senator released a letter seeking information from state-level chapters of the National Alliance on Mental Illness. The inquiry follows one Grassley made earlier this year asking NAMI and other patient advocacy groups and medical professional societies for information about financial relationships with drug companies and medical device manufacturers. The letter is posted with this news release at http://grassley.senate.gov and http://finance.senate.gov.

“Public trust and public dollars are at stake,” Grassley said. “People rely on medical advice and taxpayers spend billions of dollars on prescription drugs and devices through Medicare and Medicaid. Public confidence could be greatly improved if financial relationships were disclosed. My legislative effort is a common-sense reform that would require the pharmaceutical and device industry to report the money it gives to doctors.”

Read entire article: http://www.iowapolitics.com/index.iml?Article=174518

« Return to news items


  • Share/Bookmark

Grassley’s NAMI Invest Should Include Whistleblower Suit: Claims NAMI promoted off label use of antipsychotics in kids

Thursday, October 22nd, 2009

Jim Edwards
BNET
October 22, 2009

Sen. Charles Grassley is investigating the National Alliance for the Mentally Ill, the New York Times reports. He might want to look into Pfizer’s $2.3 billion Bextra settlement as one of the suits within it made some juicy claims about how NAMI works.

NAMI is supposed to represent mentally ill people, not drug companies, but executive director Michael Fitzpatrick agrees Big Pharma’s influence over the organization has been excessive. The Times:

“I understand that NAMI gets painted as being in the pockets of pharmaceutical companies, and somehow that all we care about is pharmaceuticals,” Mr. Fitzpatrick said. “It’s simply not true.”

To underline the point, the Times describes this NAMI gala at the Andrew W. Mellon Auditorium in Washington:

Tickets were $300 each. Before a dinner of roasted red bell pepper soup, beef tenderloin and tilapia, Dr. Stephen H. Feinstein, president of the alliance’s board, thanked Bristol-Myers Squibb, the pharmaceutical company.

Read entire article: http://industry.bnet.com/pharma/10004934/grassleys-nami-probe-may-want-to-look-at-pfizer-whistleblower-suit/

« Return to news items


  • Share/Bookmark

National Alliance on Mental Illness (NAMI) – A Pharma front group

Thursday, October 22nd, 2009

The Citizens Commission on Human Rights (CCHR) states it is no wonder that the National Alliance on Mental Illness (NAMI), a group that claims to be an advocacy organization for people with “mental illness,” opposed the black box warnings on antidepressants causing suicide for under 18 year olds in 2004, and black box warnings on ADHD drugs causing heart attack, stroke and sudden death in children in 2006, when you look at their biggest source of funding: Pharma.

Today’s New York Times article, “Drug Makers Are Advocacy Group’s Biggest Donors” states “A majority of the donations made to the National Alliance on Mental Illness, one of the nation’s most influential disease advocacy groups, have come from drug makers in recent years, according to Congressional investigators. The alliance, known as NAMI, has long been criticized for coordinating some of its lobbying efforts with drug makers and for pushing legislation that also benefits industry. Last spring, Senator Charles E. Grassley, Republican of Iowa, sent letters to the alliance and about a dozen other influential disease and patient advocacy organizations asking about their ties to drug and device makers. The request was part of his investigation into the drug industry’s influence on the practice of medicine.

The mental health alliance, which is hugely influential in many state capitols, has refused for years to disclose specifics of its fund-raising, saying the details were private. But according to investigators in Mr. Grassley’s office and documents obtained by The New York Times, drug makers from 2006 to 2008 contributed nearly $23 million to the alliance, about three-quarters of its donations.”

Read NY Times article here: http://www.nytimes.com/2009/10/22/health/22nami.html?_r=2

More on NAMI:

    • NAMI’s pharmaceutical funding was first exposed in the November 1999  Mother Jones article  “An influential mental health nonprofit finds its grassroots funded by Pharmaceutical millions,”  Internal documents obtained by Mother Jones found 18 drug firms gave NAMI a total of $11.72 million between 1996 and mid-1999. These include Janssen ($2.08 million), Novartis ($1.87 million), Pfizer ($1.3 million), Abbott Laboratories ($1.24 million), Wyeth-Ayerst Pharmaceuticals ($658,000), and Bristol-Myers Squibb ($613,505).  And that NAMI’s leading donor was Eli Lilly and Company, maker of Prozac, which gave $2.87 million during that period. In 1999 alone, Lilly will have delivered $1.1 million in quarterly installments, with the lion’s share going to help fund NAMI’s ‘Campaign to End Discrimination’ against the mentally ill.”

    • In a 2000 Insight Magazine article, NAMI spokesperson Bob Carolla stated, “Mental illness is a biologically based brain disorder” and deferred to the U.S. Surgeon General’s 1999 Report on Mental Health as evidence of this. Yet the author of the article, Kelly Patricia O’Meara reviewed the entire report looking for this evidence, and found, “The Surgeon General’s report does not provide a single piece of scientific data supporting mental illness as a brain disorder or disease.”

    Factually, the Surgeon General’s report admitted there is no medical proof to substantiate NAMI’s claims. The report states, “The diagnoses of mental disorders is often believed to be more difficult than diagnoses of somatic or general medical disorders since there is no definitive lesion, laboratory test or abnormality in brain tissue that can identify the illness.”

    Psychiatrist Loren Mosher, former Chief of Schizophrenic Research Studies National Institute of Mental Health (NIMH) stated, “The National Alliance for the Mentally Ill (NAMI) gets the pharmaceutical money and then says they spend it on their ‘antistigma’ campaign. They say that mental illness is a ‘brain disease.’ And it works well for the people who suffer from this to use their drugs. This is why NAMI is pushing for forced medication. It is an amazing selling job on the part of NAMI.”

    • December 18, 2003, The New York Times reported that NAMI bused scores of protestors to a hearing in Frankfort, Kentucky, took out full page ads in Kentucky newspapers, and sent angry faxes to state officials, all protesting a state panel proposal to exclude the antipsychotic drug Zyprexa from Medicaid’s list of preferred medications. According to the article, “What the advocacy groups did not say at the time was that the buses, ads and faxes were all paid for” by the manufacturer of the antipsychotic drug Zyprexa, Eli Lilly.

    In 2004, NAMI opposed the FDA issuing “black box” warnings on antidepressants about their increased risk of suicidal thoughts and behaviors in under 18-year-olds.

    In 2006, despite overwhelming evidence of serious adverse cardiac events and sudden deaths caused by ADHD drugs, NAMI took the position that the “black box” warning on ADHD drugs was “premature.”

If NAMI was truly a patient’s rights advocacy group as they purport to be, the question must be asked why they opposed legislation that forwards patients rights.

Take for example the Child Medication Safety Act, a bill that passed the House of Representatives 425-1 in 2003. The bill stated that as a condition of receiving federal funds, states develop policies and procedures that prohibit schools from requiring a child to take psychiatric drugs as a condition of attending school. NAMI reported in their Policy Alerts section of their Beginnings newsletter that summer that they were “not opposed to the intent of the bill.” However, in the same article they stated “given the bill’s stern enforcement provisions—threatening the loss of federal education funds—it’s enactment would inevitably have a chilling effect on schools across the country.” They went on to encourage people contact their Senators to “express concern” about the bill.

Despite NAMI’s efforts, the bill, hailed as a protection for parents rights, was passed in December 2004 as the Prohibition on Mandatory Medication Amendment, a bill CCHR and many other concerned groups had been strongly in support of, after numerous parents came forth stating they had been forced to have their children take psychiatric drugs as a condition of attending school, and even had been charged with medical neglect for failing to comply.

« Return to news items


  • Share/Bookmark

Congressman Ron Paul’s Parental Consent Act

Wednesday, October 14th, 2009

Ron PaulBy John Breeding
Psychologist, Author, The Wildest Colts Make the Best Horses
October 14, 2009

On April 30, 2009, Congressman Ron Paul introduced H.R. 2218, known as The Parental Consent Act of 2009.

The bill forbids federal funding for universal or mandatory mental health screening, and also forbids money for any educational or other government agency that would use a parent’s refusal to consent to their child’s screening as basis for a charge of child neglect or abuse.



A little recent history is relevant. On April 29, 2002, President George Bush created the New Freedom Commission on Mental Health. In 2003, this industry-studded commission presented their recommendations for the reform of the United States mental health system.

“To aid in transforming the system,” the authors of the report wanted to do many things, including:

  • Improve and expand school mental health programs.
  • Screen for co-occurring mental and substance use disorders and link with integrated treatment strategies.
  • Screen for mental disorders in primary health care, across the lifespan, and connect to treatment and supports.

This rhetoric serves to hide the truth that New Freedom is better called No Freedom or New Intrusion, and that mental health screening really means mass marketing and target recruitment of a captive population.

By the time of these New Freedom Commission recommendations, there already existed very large numbers of citizens around the country wising up to the extraordinary intrusion of psychiatry into our schools, as demonstrated in the first four years of this millennium by a number of resolutions, education department statements and state laws, all defending a parent’s right to make treatment decisions for a child without coercion, and a child’s right to education without psychiatric labeling and drugs.

Through 2003, there had been at least 46 state bills or resolutions supporting parental choice, in 28 states, that had either passed or were still pending action across the United States.  For example, Connecticut, Minnesota and Texas had passed laws explicitly stating that a parent’s refusal to consent to the administration of a psychotropic drug to a child does not constitute neglect, therefore is not in itself grounds for Child Protective Services (CPS) investigation.  Other states have passed related laws either monitoring or curbing CPS policy in this area.

Many states are pursuing related legislation as the wave of activity in support of parental choice continues to expand.  Texas law now prohibits school personnel from suggesting a diagnosis or recommending a psychotropic drug to a parent for their child.  The public will is clearly for the schools to educate, not medicate, and for the state to allow privacy and autonomy to parents and families.  At a federal level the fight over the Child Medication Safety Act was eventually won so that nowhere in the country is it legal to require a psychiatric controlled substance as a condition of attending school.

Ron Paul has been a key leader in this effort for some time.  On October 6, 2004, he introduced an earlier incarnation of his current Parental Consent Act.  This one, aptly titled the Let Parents Raise Their Kids Act, also attempted to forbid federal funds from being used for any universal or mandatory mental-health screening of students without the express, written, voluntary, informed consent of their parents or legal guardians.

Since that time, the fight has only intensified.  In 2005 in Texas, for example, we fought tooth and nail to the bitter end to defeat a bill that would have initiated mental health screening in schools throughout Texas.  Since we have defeated them consistently, this session they tried to get a pilot program approved for San Antonio and we defeated that as well, but the psychiatric and pharmaceutical lobbies are relentless.  PsychSearch.net provides one of the best websites on mental health screening and the ongoing resistance.

We have been aided by our awareness.  Made possible largely by the work of Pennsylvania whistleblower Allen Jones, we know that many of the New Freedom commissioners are linked directly or indirectly to the Texas Medication Algorithm Project (TMAP), which provides formulas recommending specific psychotropic drugs to treat various “mental illnesses.”  It has been revealed that TMAP pushed an off-label drug marketing scheme that appears to skirt federal law.  We know, therefore, that this commission’s recommendations are intended to encourage an expansion of the fact that “appropriate services” in today’s psychiatric world means psychotropic drugs; there are already millions upon millions of school-age children on psychiatric drugs.

Senator Charles Grassley’s work outing the severe ethical financial conflicts of so many psychiatric industry spokespersons makes it a little easier to challenge these things.  For example, it tends to impress legislators when they hear that three psychiatry department chairs—Charles Nemeroff of Emory University ($1 million from GlaxoSmithKline alone), Martin Keller of Brown University (associated with a severely compromised drug trial) and Alan Shatzberg of Stanford (who was principal investigator on a drug developed by a company in which he owned $6 million of stock) have all recently resigned their positions as a result of Grassley’s investigation.

The very high number of false positives in mental health screening is good data.  In one study at Columbia University, the authors concluded that use of the Columbia Suicide Screen would result in 84 non-suicidal teens being referred for further evaluation for every 16 youths correctly identified.  It also helps to know that these type programs tend not to work anyway.  For example, the United States Preventive Services Task Force (USPSTF) found that screening for suicide risk does not reduce suicide attempts or mortality.

Finally, the facts about the severe dangers and lack of efficacy of the various types of psychiatric drugs gets attention once the truth is made known.

I consider this to represent a tragic situation, and a clear and present danger to our children.  Here is a pledge that thousands specifically signed and that so many more are acting on in the concerted challenges around the country to this scourge:

We promise to actively resist further intrusion of psychiatry into the public schools, and will not cooperate in any way with those who act as agents of this wrong-headed government initiative.  We do not now and will not later consent to the psychiatric or psychological testing of our children by those who act as agents to implement New Freedom recommendations for universal mental health screening of our children.

The Parental Consent Act of 2009 is a great idea. Passing this bill in Washington would make a significant difference in protecting children and families against further intrusion of psychiatry into the schools. I know it would also make this Texas activist’s life a little easier!

John Breeding, Ph.D. has been a counseling psychologist in Austin, Texas for 25 years. He is the director of Texans For Safe Education, a citizens group dedicated to challenging the ever-increasing role of psychiatric drugs in schools.  He is the author of numerous articles and four books including: The Wildest Colts Make the Best Horses and True Nature and Great Misunderstandings: On How We Care For Our Children According To Our Understanding.

Click here to read The Parental Consent Act

Contact your member of Congress to support The Parental Consent Act. To find your Representative and get their contact information, go to http://www.congress.org/congressorg/directory/congdir.tt to look them up (you need to enter your zip code).

RETURN TO BLOGS PAGE


  • Share/Bookmark